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studies use local institutional approaches to manage imaging 
information for these purposes?  
All these issues need to be resolved before widespread 
implementation into clinical practice can take place. 
Molecular and functional imaging and its evaluation has to be 
validated and proven to be useful in multicenter studies. 
Advanced solutions need to be established to incorporate 
multiparameter information from e.g. tumor biopsy 
immunohistochemical analysis and gene-arrays into decision-
making processes for specific imaging modalities, 
individualized treatment and treatment evaluation pathways. 
The first multicenter studies with these goals in mind are 
now being established. 
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Changes in the tumoras well as normal tissues and organs 
surrounding the tumor during and/or in response to radiation 
therapy require treatmentadaptation. A need for adaptive 
radiation therapy (ART) is not obvious for alltumors, but 
head-and-neck cancer, for which substantial changes in 
tumor andparotid gland geometry and dosimetry have been 
shown [1]. Moreover, biologicchanges in the tumor may 
require treatment adaptationas well [2]. Logistics of ARTis 
complex and hampered by a lack of personnel and robust 
technical tools. Theworkflow is usually not well-defined and 
well-supported by commercial oncologyinformation and 
treatment planning systems. Nevertheless, an increasing 
numberof academic centers introduce ART in their practice 
as has done it inDepartment of Radiotherapy, Ghent 
University Hospital. In this talk theworkflow of ART for head-
and-neck cancer on the example of this particularcenter will 
be discussed in more detail including the roles of personnel 
withemphasis on RTTs, their current responsibilities and their 
possible empowermentin the frame of ART.  
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In the ARTForce project, two international clinical trials are 
conducted. The first trial (NCT01504815) for locally advanced 
head-and-neck cancer patients is a phase two trial 
randomizing between standard chemo-radiotherapy, 
redistributing the dose in the PTV of the primary tumor. 
Instead of a homogeneous dose of 70Gy in 35 fractions, an 
inhomogeneous dose is optimized based with a minimum dose 
of 64 Gy at the edge of the PTV and a maximum dose of 84 
Gy around the FDG PET SUVmax location. Additionally, in the 
experimental arm, the treatment plan is adapted after two 
weeks to account for anatomical changes. The second phase 
2 trial (NCT01024829) for locally advanced lung cancer 
patients randomizes between dose escalation to the primary 
tumor >= 72 Gy in 24 fractions and dose escalation to the 
region of the tumor defined by the 50% of FDG PET SUVmax. 
Both treatment plans are optimized to have an equal mean 
lung dose. In this presentation, dosimetric differences 
between the arms in both trials will be discussed as well as 
the impact of anatomical changes on the delivered dose and 
the effectiveness of replanning to mitigate dose 
discrepancies. 
 
Symposium: Secondary cancer after radiotherapy: from 
cancer registries to clinical implications  
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Second cancers are an important cause of morbidity and 
mortality in cancer survivors. One in five cancers diagnosed 
in the US are now second cancers. The causes of second 
cancers include lifestyle factors, genetic predisposition and 
also the treatment for the first cancer, including 
radiotherapy. In the last decade there have been a large 
number of new studies that have advanced our understanding 
of the risk of second cancers after radiotherapy. The most 
informative studies provide dose-response relationships based 
on individual dose-reconstruction. These studies suggest that 
the second cancer risk generally increases linearly with dose, 
even at organ doses of ≥60Gy. This is contrary to earlier 
theories that the dose-response would flatten or even have a 
down-turn at higher doses because of cell killing. The 
magnitude of the risk from these fractionated high-dose 
exposures is, however, 5-10 times lower than the risk from 
acute exposures of <2Gy among the Japanese atomic bomb 
survivors. The results from these detailed observational 
studies provide insights into radiation carcinogenesis from 
fractionated high-dose exposures, and can be used to develop 
second solid cancer risk projection models for newer 
radiotherapy techniques. 
 
SP-0437  
Modelling of secondary cancer risks 
U. Schneider
1Clinic Hirslanden Zürich, Institute of Radiotherapy, Zürich, 
Switzerland 
1,2 
2University of Zürich, Institute of Physics- Science Faculty, 
Zürich, Switzerland 
 
In developed countries, more than half of all cancer patients 
receive radiotherapy at some stage in the management of 
their disease. However, a radiation-induced secondary 
malignancy can be the price of success if the primary cancer 
is cured or at least controlled. Therefore, there is increasing 
concern regarding radiation-related second cancer risks in 
long-term radiotherapy survivors and a corresponding need to 
be able to predict cancer risks at high radiation doses. Of 
particular interest are second cancer risk estimates for new 
radiation treatment modalities such as intensity modulated 
radiotherapy, intensity modulated arc-therapy, proton and 
heavy ion radiotherapy. The long term risks from such 
modern radiotherapy treatment techniques have not yet 
been determined and are unlikely to become apparent for 
many years, due to the long latency time for solid tumor 
induction. Most information on the dose-response of 
radiation-induced cancer is derived from data on the A-bomb 
survivors who were exposed to gamma-rays and neutrons. 
Since, for radiation protection purposes, the dose span of 
main interest is between zero and one Gy, the analysis of the 
A-bomb survivors is usually focused on this range. With 
increasing cure rates, estimates of cancer risk for doses 
larger than one Gy are becoming more important for 
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radiotherapy patients. Simple radiation protection models 
should be used only with extreme care for risk estimates in 
radiotherapy, since they are developed exclusively for low 
dose. When applied to scatter radiation, such models can 
predict only a fraction of observed second malignancies. 
Better semi-empirical models include the effect of dose 
fractionation and represent the dose-response relationships 
more accurately. The involved uncertainties are still huge for 
most organs and tissues. A major reason for this is that the 
underlying processes of the induction of carcinoma and 
sarcoma are not well known. Most uncertainties are related 
to the time patterns of cancer induction, the population 
specific dependencies and to the organ specific cancer 
induction rates. For radiotherapy treatment plan 
optimization these factors are irrelevant, as a treatment plan 
comparison is performed for a patient of specific age, sex, 
etc. If a treatment plan is compared relative to another one 
only the shape of the dose-response curve (the so called risk-
equivalent dose) is of importance and errors can be 
minimized. One of the largest remaining uncertainties is the 
precision of the dose distribution which is the basic input into 
all risk-estimate-models. Dose calculation and/or 
measurement are as precise as approximately 5% in the 
treated volume of the patient. However, in the periphery 
dose errors can reach 100% and more. The use of erroneous 
dose data (see Figure 1) can lead to wrong risk estimates. 
Therefore a lot of effort is undertaken to produce precise 
dose computations in the whole patient volume about which 
is reported. Strategies are discussed how to include relevant 
dose information into cancer registries. 
Figure 1. Two dose comparisons of the same radiation 
treatment techniques which were used for risk estimates. 
The resulting risk estimates were highly contradictory.  
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The association between radiation exposure and cancer risk 
has been studied for several decades, although in the clinical 
oncology setting, significant gaps in the understanding and 
management of radiation therapy (RT) related second cancer 
risks still exist. 
This talk will address the clinical implications of current 
knowledge relating to treatment- related second cancers, 
including:  
1. Treatment selection: Some clinicians or patients may opt 
to avoid RT in order to reduce the risk of second cancers. 
These decisions often reveal important misunderstandings 
about the impact of age, competing risks of death or other 
morbidity, and differences between absolute and relative 
risks. Through a case-based approach, participants will learn 
to identify scenarios in which over- or under-estimation of 
second cancer risk may lead to suboptimal treatment 
choices.  
2. Modification of Radiation Treatment: Oncologists are able 
to deliver dose much more precisely than ever before, but it 
remains difficult to decide where to deposit excess dose, or 
if low doses to large volumes are more carcinogenic than high 
doses to small volumes. The emergence of proton therapy 
now adds further complexity to these issues. In this session, 
participants will learn about dose-risk relationships and the 
clinical implications for radiotherapy planning. 
2. Clinical management in follow-up: Survivorship care is of 
growing clinical concern, and management of second cancer 
risk is an important feature of this care. Oncologists will be 
required to have familiarity with guidelines recommending 
specific screening interventions following RT. Participants 
will learn about resources and guidelines for management of 
second cancer risk, and the evidence supporting these 
guidelines will be reviewed. 
 
Proffered Papers: Radiobiology 4: Molecular biomarkers for 
patient selection  
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Purpose or Objective: The influence of HPV positivity on 
therapy response in head and neck squamous cell cancers 
(HNSCC) highlights the importance of uniform and robust 
biomarkers for stratification of HNSCC patients. Our previous 
report indicates that p16 is not only a surrogate marker for 
HPV infections but has an active role in modulation of 
radiotherapy response by impairing DNA damage response 
and repair, which is a process known to be dominant in the 
nucleus of the cells. Based on this, we hypothesized that p16 
compartmentalization according to nuclear and cytoplasmic 
expression may have a role in risk stratification. 
 
Material and Methods: p16 expression (immunostaining) and 
HPV status (GP5+/6+ PCR) was assessed in 241 pretreatment 
biopsies of oropharyngeal cancer patients treated with 
chemoradiotherapy. Tumors were classified in nuclear p16 
expressing (>10% of tumor cells), cytoplasmic (>10% tumor 
cells) and p16 negative groups. Statistical analysis was 
performed to assess the correlation between clinical and 
tumor characteristics and p16 immunostaining. Influence of 
p16 localization on radiotherapy response was further 
assessed by clonogenic and cell survival assays in HPV/p16 
negative HNSCC cells transfected with viral construct 
containing p16-NLS (nuclear localization signal); p16-NES 
(nuclear exit signal) and p16-WT. The expression and 
localization of p16 was confirmed by western blotting and 
immunofluorescence. The response of p16 localization on 
DNA damage response and homologous recombination repair 
(HRR) was assessed by gH2AX, RAD51 foci formation and 
immunoprecipitation. 
 
Results: Nuclear p16 expressing HNSCC showed significant 
(p<0.05) better locoregional control rates (5-year 82%) 
compared to cytoplasmic p16 positive (5-year 55%) and p16 
negative patients (5-year 48%). Only nuclear p16 expression 
was a significant prognostic factor for locoregional control 
with a hazard ratio of 0.48 (p<0.05; 95% CI: 0.22-1.01). 
Interestingly, HPV positive patients were significantly 
enriched in the nuclear p16 expressing group (60%) compared 
to cytoplasmic p16 expressing group (9%). In concordance 
with our patient data, cells containing nuclear p16 expression 
(p16-NLS) showed a higher radiosensitization compared to 
cells with predominant cytoplasmic p16 expression (p16-NES) 
